$RNXT News

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

RenovoRx, Inc. Q1 2026 Earnings Call Summary

RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript

RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.

RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13.5